Home » Stocks » BLFS

BioLife Solutions, Inc. (BLFS)

Stock Price: $40.33 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $39.51 -0.82 (-2.03%) Jan 15, 4:24 PM
Market Cap 1.32B
Revenue (ttm) 41.66M
Net Income (ttm) -11.39M
Shares Out 31.64M
EPS (ttm) 0.12
PE Ratio 341.78
Forward PE 666.67
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $40.33
Previous Close $40.33
Change ($) 0.00
Change (%) 0.00%
Day's Open 42.12
Day's Range 39.88 - 42.60
Day's Volume 428,919
52-Week Range 8.36 - 45.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Despite MedTech industry's bright prospects in 2021, investors should be wary of stocks like BLFS, STAA and TGTX, given their unfavorable Zacks Rank and weak fundamentals.

Other stocks mentioned: STAA, TGTX
Seeking Alpha - 2 months ago

BioLife Solutions, Inc.'s (BLFS) CEO Michael Rice on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

BOTHELL, Wash., Nov. 5, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...

PRNewsWire - 3 months ago

BOTHELL, Wash., Oct. 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproducti...

Seeking Alpha - 3 months ago

Q2 2020 was a stellar quarter for BLFS in terms of revenue generation and new customer onboarding.

The Motley Fool - 3 months ago

It's a classic vertical integration move.

PRNewsWire - 4 months ago

BOTHELL, Wash., Aug. 25, 2020 /PRNewswire/ -- BioLife Solutions, Inc.

Seeking Alpha - 5 months ago

Biolife Solutions, Inc. (BLFS) CEO Michael Rice on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

BOTHELL, Wash., Aug. 6, 2020 /PRNewswire/ -- BioLife Solutions, Inc.

Zacks Investment Research - 5 months ago

BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

PRNewsWire - 5 months ago

BOTHELL, Wash., July 30, 2020 /PRNewswire/ -- BioLife Solutions, Inc.

PRNewsWire - 6 months ago

BOTHELL, Wash., July 7, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...

Zacks Investment Research - 6 months ago

BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 6 months ago

BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

The Motley Fool - 6 months ago

It doesn't look like the COVID-19 pandemic had much effect on sales of the company's bioproduction products for cell and gene therapies.

PRNewsWire - 6 months ago

BOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...

PRNewsWire - 6 months ago

BOTHELL, Wash., July 1, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...

PRNewsWire - 7 months ago

BOTHELL, Wash., May 18, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction...

Seeking Alpha - 8 months ago

The company experienced a 50% increase in its media revenues, although a considerable part of that is probably inflated by safety inventory building customers.

Seeking Alpha - 8 months ago

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 8 months ago

BOTHELL, Wash., May 14, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproductio...

Zacks Investment Research - 8 months ago

BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Seeking Alpha - 9 months ago

BioLife Will Suffer From Cancellations Of Trials

Seeking Alpha - 10 months ago

BioLife Solutions' (BLFS) CEO Mike Rice on Q4 2019 Results - Earnings Call Transcript

Investopedia - 11 months ago

BioLife Solutions shares opened higher before moving sharply lower Thursday despite a higher analyst price target.

Seeking Alpha - 1 year ago

BioLife's Disappointing Quarter Masks A Much Better Future

Seeking Alpha - 1 year ago

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Biolife Solutions Digesting Big Gains; More To Follow

Seeking Alpha - 1 year ago

The shares of BioLife have sold off last month, and those of competitor CryoPort much more, closing what we thought was an irrational valuation gap.

Zacks Investment Research - 1 year ago

Medical Products Industry Outlook: Prospects Seem Promising

Other stocks mentioned: APHA, SRDX
Seeking Alpha - 1 year ago

BioLife Solutions, Inc. (BLFS) CEO Mike Rice on Q2 2019 Results - Earnings Call Transcript

GuruFocus - 1 year ago

CFO of Biolife Solutions Inc (30-Year Financial, Insider Trades) Greef Roderick De (insider trades) sold 30,000 shares of BLFS on 08/02/2019 at an average price of $18.96 a share.

Zacks Investment Research - 1 year ago

BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

We noticed a huge and recent valuation gap between BioLife and CryoPort, both operating in the regenerative medicine market supplying storage media and distribution solutions.

Seeking Alpha - 1 year ago

Shares have risen by over 150% since my initial recommendation.

Seeking Alpha - 1 year ago

Both companies operate in the same market and are of similar size and produce comparable growth rates, yet CryoPort sells at 2.5x the valuation of BioLife.

Other stocks mentioned: CYRX
Seeking Alpha - 1 year ago

We argued that the company is a ground-floor opportunity on the regenerative medicine revolution, which is just in the early innings.

Seeking Alpha - 1 year ago

Biolife Solutions' (BLFS) CEO Mike Rice on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

BioLife (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

One of our top picks in the SHU portfolio is BioLife Solutions, the maker of proprietary preservation solutions for cells, tissues, and organs.

Seeking Alpha - 1 year ago

Biolife Solutions, Inc. (BLFS) CEO Michael Rice on Q4 2018 Results - Earnings Call Transcript

About BLFS

BioLife Solutions develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial an... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Nov 22, 1989
CEO
Michael Rice
Country
United States
Stock Exchange
NASDAQ
Ticker Symbol
BLFS
Full Company Profile

Financial Performance

In 2019, BLFS's revenue was $27.37 million, an increase of 38.64% compared to the previous year's $19.74 million. Losses were -$1.66 million, -93.37% less than in 2018.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for BLFS stock is "Buy." The 12-month stock price forecast is 44.21, which is an increase of 9.62% from the latest price.

Price Target
$44.21
(9.62% upside)
Analyst Consensus: Buy